Navigation Links
Combination therapy shows promising results in patients with advanced lung cancer

advanced lung cancer.

The study was part of the Specialized Program of Research Excellence (SPORE) in lung cancer at UCLA's Jonsson Cancer, a program funded by the National Cancer Institute at top research institutions nationwide to find better and more effective ways to prevent, detect and treat lung cancer.

"This trial is an important early step in utilizing combination targeted therapies in lung cancer," said Dr. Steven Dubinett, director of UCLA's lung cancer SPORE and a professor of pulmonary and critical care medicine. "Dr. Reckamp's trial is the first to study increasing doses of a COX-2 inhibitor in lung cancer in an attempt to define an optimal biological dose. Larger trials of combination therapies utilizing this dose will now be required."

The biology of an individual's tumor determines whether they will respond to Tarceva. Because researchers don't yet fully understand what biologic characteristics determine response, they can't test patients first to determine who should be given the drug. Since 90 percent of patients don't respond to Tarceva, the drug was not an option for them. Reckamp said a portion of those may now be able to take Tarceva combined with Celebrex.

Because they target what is broken in a cancer cell and leave the healthy cells alone, therapies like Tarceva cause fewer side effects than conventional therapies such as chemotherapy, which targets all fast growing cells and often results in debilitating side effects. Reckamp characterized the side effects seen with the combination therapy as minor.

The next step is a larger Phase II study to confirm the efficacy of the combination therapy and further probe the mechanisms of Tarceva resistance, Reckamp said. That study is expected to begin at UCLA in the fall.

Reckamp's study was the first to determine the safest and most effective dose of Celebrex to use in lung cancer. Previously, doses were based on studies done in colon cancer patients.'"/>

Source:University of California - Los Angeles


Page: 1 2 3

Related biology news :

1. Combination therapy boosts effectiveness of telomere-directed cancer cell death
2. Combination therapy leads to partial recovery from spinal cord injury in rats
3. Combination therapy improves AIDS-related lymphoma outcome
4. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Gene therapy converts dead bone graft to new, living tissue
8. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
9. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
10. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
11. New therapy for HIV/AIDS eliminates needles and excessive toxicity

Post Your Comments:
(Date:11/4/2009)...ancouver, BC - Lowly bacteria, it turns out, hold ...turing plants around the world clean up toxic wast..., specifically RDX, were invented back in World Wa...decades. These high-energy compounds are often us...ful version of TNT. , But with increased knowl...
(Date:11/4/2009)...he University of Oklahoma at Norman has received m...funding agencies as part of the federal stimulus p...ng received by OU researchers to $23 million. Thi...search ranging from archaeology to weather. , "T...atic approach to matching areasof scholarly excell...
(Date:11/4/2009)..., MADISON, N.J., Oct. 20 /PRNewswire-FirstCall/ -...e world,s leading provider of diagnostic testing, ...hird quarter ended September 30, 2009, income from....02 per diluted share, from $160 million, or $0.81... In 2008, third quarter results were reduced by a ...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Milliman Report Addresses the Potential Impact of Height and Weight on Medical Costs 57198 1Milliman Report Addresses the Potential Impact of Height and Weight on Medical Costs 57198 2LodgeNet Interactive to Present at the CL King Best Ideas Conference 57196 1LodgeNet Interactive to Present at the CL King Best Ideas Conference 57196 2LodgeNet Interactive to Present at the CL King Best Ideas Conference 57196 3LodgeNet Interactive to Present at the CL King Best Ideas Conference 57196 4LodgeNet Interactive to Present at the CL King Best Ideas Conference 57196 5Canadian researchers discover the first ever link between intelligence and curiosity 57194 1Canadian researchers discover the first ever link between intelligence and curiosity 57194 2
...his press release is available in German . , Wi...ecks above all at airports has been increased co...concerns the protection of passengers. Possibiliti...e offered by terahertz radiation. Before this radi...s to be measured quantitatively, so that damage to...
...erts from the worlds of law, geography, economics,...(University College London) on Friday September 19...es can become locally-rooted champions for global ...y to help bring about lasting change. The symposiu...elating Ecological Thinking, Learning and Research...
...logists at the University of Rochester have found ... evolved a previously unknown anti-cancer mechanis... mechanisms employed by humans or other large mamm...f Aging Cell. , Understanding this mechanism may ...ancers originate from stem cells and similar mecha...
Other Biology News:Checking people at airports -- with terahertz radiation 2Universities develop a more sustainable future 2Novel anti-cancer mechanism found in long-lived rodents 2
(Date:11/6/2009)...,, QUINCY, Mass., Nov. 6 Myrian...biotech developer and manufacturer of renewable b...preferred technology provider Uhde GmbH, one of th... "Uhde"), announced an alliance for the engineerin...,s biobased Succinic Acid plants based on renewabl...
(Date:11/6/2009)...,, CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Onc...lytics" or the "Company") today announced updated ...SIN(R) in patients with sarcomas metastatic to the...Connective Tissue Oncology Society Meeting held in...he poster presentation, entitled "A Phase II Study...
(Date:11/5/2009)...,, GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstC...ced its financial results for the third quarter en... of $3.6 million ($0.04 per share) for the three m...oss of $6.8 million ($0.08 per share) in the compa...eptember 30, 2009, GenVec,s net loss was $14.1 mil...
(Date:11/5/2009)...,, RANCHO CORDOVA, Calif., Nov. 5 /PRNewswire-F... a leading supplier of innovative products for pro...ed results for the first quarter of fiscal 2010. ,... Company reported revenues of $5.2 million, a 15 p...he first quarter a year ago. The Company said the ...
Breaking Biology Technology:Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...world-leading flow measurement and control provide...ntroller, a totally new family of mass flow produc...ressure and temperature. Built on a standard 1.125... and local digital display, the B-Series provides ...ich eliminates the need for costly temperature and...
...l Indians , , - Leverages Satyam,s earlier succe... Satyam Computer Services Limited, (NYSE: SAY ) ...logy services provider, announced today that it wa... with a Consumer Health World Award for a tele-oph...rdable eye care to Indian villages. , , The Cons...
...NYSE Alternext US: DDD) today reported financial r...ber 31, 2008. The Company will host a live confer...stern Daylight Time). , , "Last year was an impor...CEO Bruce S. Morra, Ph.D., M.B.A. "Utilizing our u...ss advancing our two primary over-the-counter (OTC...
Other Biology Technology:Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 2Brooks Instrument's New Mass Flow Controller Series Is Immune to Pressure and Temperature Fluctuations 3Satyam Wins Consumer Health World Award for Tele-Ophthalmology Program 2Satyam Wins Consumer Health World Award for Tele-Ophthalmology Program 3Satyam Wins Consumer Health World Award for Tele-Ophthalmology Program 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 2SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 3SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 4SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 5SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 6SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 7SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results 8
BLOCK-iT siRNA, Stealth and Custom RNA from Invitrogen
...atoms at the 9, 10, 12, and 13 positions. It is in...ntification of 13(S)-HODE by GC- or LC-mass spectr...noleic acid with plant and mammalian lipoxygenases...or cells to the endothelium at concentrations arou...
Adaptor BamH I-Sma I from Takara Mirus Bio
Cassette, Hind III from Takara Mirus Bio
Biology Products: